Jankovic J
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030.
Mov Disord. 1994 May;9(3):347-9. doi: 10.1002/mds.870090315.
Botulinum toxin (BTX) injections provide effective treatment for a variety of disorders manifested by inappropriate muscle contractions, but its efficacy in the treatment of tics has not been previously studied. Ten male patients 13-53 years of age who were diagnosed with Tourette's syndrome manifested by disabling focal tics were included in this pilot study. Five patients had frequent blinking and blepharospasm, rendering them "blind," and five patients had severe and painful dystonic tics involving their neck muscles. All 10 patients experienced moderate to marked improvement in the intensity and frequency of tics after BTX injections into the involved muscles. Patients in whom premonitory urges preceded their tics noted marked lessening of these sensory symptoms. The benefit lasted 2-20 weeks after injections. There were no serious complications, except for transient ptosis in two and neck pain, stiffness, or weakness in three patients. BTX injections appear to be safe and effective treatment for patients with focal dystonic tics. The treatment ameliorates not only involuntary movements but also the premonitory sensory component associated with some tics.
肉毒杆菌毒素(BTX)注射可为各种因肌肉收缩不当而引发的疾病提供有效的治疗方法,但此前尚未对其治疗抽动症的疗效进行研究。本试点研究纳入了10名年龄在13至53岁之间、被诊断为患有以致残性局灶性抽动为表现的妥瑞氏综合征的男性患者。5名患者频繁眨眼和眼睑痉挛,导致他们“失明”,另外5名患者颈部肌肉出现严重且疼痛的张力障碍性抽动。在对受累肌肉注射BTX后,所有10名患者的抽动强度和频率都有中度到显著的改善。抽动前有预感冲动的患者注意到这些感觉症状明显减轻。注射后疗效持续2至20周。除了两名患者出现短暂上睑下垂,三名患者出现颈部疼痛、僵硬或无力外,没有严重并发症。BTX注射似乎是治疗局灶性张力障碍性抽动患者的安全有效方法。该治疗不仅可改善不自主运动,还可改善与某些抽动相关的预感感觉成分。